This trial blows both of those results out of the water
[Source: Fierce Pharma ] January 2025 The FDA fast-tracked tirzepatide for cardiovascular risk reduction in obesity patients, following landmark trial results showing significant benefit beyond weight loss
One activates two receptors
About this article Cite this article Pereira, M.J., Eriksson, J.W
A person with a BMI of 28 and a history of gestational diabetes may benefit from one of these medications to lose weight while concomitantly mastering lifestyle behaviors, and then transition off the weight management medications to lifestyle alone, says Linda Gigliotti, MS, RDN, CDCES, CSOWM, an obesity and weight management specialist based in Irvine, California